FindMyKOL
Clinical trialNCT01440803CompletedPhase 2Interventional

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

NCT01440803 is a phase 2 interventional trial sponsored by Elizabeth Shane. As of 21 Nov 2026, it is completed. It studies Saline Placebo and Teriparatide in Adult Idiopathic Generalized Osteoporosis. The registry lists an enrollment of 41 participants at 2 sites in 1 country. The registry lists a start date of 2 Aug 2012 and a primary completion date of 1 Jan 2018.

SponsorElizabeth ShaneEnrollment41Adult Idiopathic Generalized Osteoporosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01440803
FieldValue
Registry IDNCT01440803
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorElizabeth Shane
Enrollment41
Registered sites2
Countries1
ConditionsAdult Idiopathic Generalized Osteoporosis
DrugsSaline Placebo and Teriparatide
Start2 Aug 2012
Primary completion1 Jan 2018
Study completion1 Feb 2019
Last update posted11 Dec 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Idiopathic osteoporosis (IOP) is defined as osteoporosis that affects young, otherwise completely healthy individuals with no secondary cause of bone loss. In the course of our prior research with premenopausal women with IOP, the investigators have shown that women with IOP have low areal bone mineral density (aBMD) at the spine, hip and forearm compared to normal women. Additionally, using noninvasive high resolution imaging of the central and peripheral skeleton and detailed analyses of transiliac crest bone biopsies, the investigators identified several features of bone quality in premenopausal women with IOP. There is currently no FDA-approved therapy for IOP in premenopausal women. However, teriparatide (Forteo) has been shown to improve bone mass and microarchitecture in postmenopausal women and is approved for men with primary or idiopathic osteoporosis, as well as men, premenopausal and postmenopausal women with glucocorticoid-induced osteoporosis. Because IOP in premenopausal women is an orphan disease, with an estimated prevalence of about 113,000 in the United States, pharmaceutical companies are unlikely to support development of therapies for this indication. Therefore, the major objective of this protocol is to establish the safety and efficacy of teriparatide in premenopausal women with IOP in a phase 2 clinical trial. All subjects will receive teriparatide as part of the study, but a randomly selected group of patients (10) will receive one year of placebo injections first before starting their two years of treatment. The remainder of subjects (30) will receive active drug only for two years. Funding Source - FDA OOPD

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Nebraska, United States1 site
  • Creighton University

    Omaha

New York, United States1 site
  • Columbia University Medical Center

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraska: 1 siteNE1MissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Saline PlaceboTeriparatide →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01440803

Each answer restates registry values shown on this page.

What is NCT01440803?

NCT01440803 is a phase 2 interventional trial sponsored by Elizabeth Shane. It studies Saline Placebo and Teriparatide in Adult Idiopathic Generalized Osteoporosis.

Who leads NCT01440803?

The registry names Adi Cohen, MD (study director, Columbia University), Elizabeth Shane, MD (principal investigator, Columbia University) and Emily M Stein, MD (study director, Columbia University) as overall officials.

Where does NCT01440803 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01440803 study?

The registered drug and biological interventions are Saline Placebo and Teriparatide.

When did NCT01440803 end?

The registry lists a primary completion date of 1 Jan 2018 and a study completion date of 1 Feb 2019. The sponsor last updated the record on 11 Dec 2019.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.